Been watching this a long time and buying on market for a few...

Been watching this a long time and buying on market for a few months plus lucky to go in the raise also.

I wouldnt worry about the hearts showing up to "pump and dump". Fundamentally this is as solid a biotech you can find at a ridic low valuation. With a phase 2a and phase 2b both targeting $1bill+ potential disease states, adequate funding and solid previous results in DKD it was only a matter of time before DXB started gaining some interest .

I keep thinking im missing something with DXB as to why it sits at $14 mill EV when there are soooo many other junior bios way behind us developmental wise... But then again PAR sat at $30 mill MC for a very long time in the lead up to the phase 2b readout and now sits $800 mill MC a year later.

Here are some peer comparisons to chew on instead of whinging about hearts turning up . MC wise BOT and IMU are similar development stage with OPT and PAR being 6 months give or take ahead of DXB.....perhaps this is why newbies are turning up.

PAR - phase 2b success awaiting phase 3 approval $800 mill mc
OPT - phase 2b success awaiting phase 3 approval $800 mill mc
NEU - phase 3 underway, phase 2a success, plus 3 x preclinical $250 mill mc
IMU - 2 x phase 2 $150 mill mc
BOT - 2 x phase 2 including 1 that failed or was questionable - $100 mill mc
ACW - phase 1 $50 mill mc
EX1 - pre clinical $30 mill mc